Telix Pharmaceuticals (NASDAQ:TLX) Shares Gap Down – Time to Sell?

Telix Pharmaceuticals Limited (NASDAQ:TLX)’s stock price gapped down before the market opened on Friday . The stock had previously closed at $12.42, but opened at $11.34. Telix Pharmaceuticals shares last traded at $11.36, with a volume of 68,628 shares traded.

Trending Headlines about Telix Pharmaceuticals

Here are the key news stories impacting Telix Pharmaceuticals this week:

• Positive Sentiment: Telix reported first-half revenue of $477 million, up 22% year over year, while adjusted EBITDA increased 146%. Precision Medicine revenue rose 27%, supported by Illuccix and Gozellix, and manufacturing revenue reached $146 million. Telix Pharmaceuticals Limited stock EBITDA and revenue report
• Positive Sentiment: Management highlighted continued investment in prostate, kidney and brain cancer programs, including $124 million of research and development spending, while expanding its global manufacturing footprint and advancing its late-stage pipeline. Telix 2026 half-year results
• Positive Sentiment: Wedbush reaffirmed its “outperform” rating and set a $22 price target, implying substantial upside based on the cited reference price. Quarterly earnings per share also exceeded consensus estimates. Wedbush rating report
• Neutral Sentiment: Telix is attracting increased discussion on HotCopper alongside other Australian-listed companies. The heightened attention may increase trading activity but does not represent a fundamental change in the investment case. HotCopper Telix investor attention
• Negative Sentiment: Telix shares were downgraded by an analyst, creating near-term pressure even though other brokers remain positive. The downgrade may reflect valuation, execution or expectations concerns following the company’s strong run and results. Why Telix shares were downgraded

Analyst Ratings Changes

A number of analysts have issued reports on TLX shares. HC Wainwright reiterated a “buy” rating and issued a $20.00 price target on shares of Telix Pharmaceuticals in a report on Tuesday, July 7th. Weiss Ratings reissued a “sell (d)” rating on shares of Telix Pharmaceuticals in a report on Friday, July 17th. Wedbush reaffirmed an “outperform” rating and issued a $22.00 target price on shares of Telix Pharmaceuticals in a report on Thursday. Royal Bank Of Canada downgraded Telix Pharmaceuticals from an “outperform” rating to a “sector perform” rating in a research report on Friday, July 17th. Finally, Citigroup restated a “buy” rating on shares of Telix Pharmaceuticals in a report on Thursday. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $20.40.

Telix Pharmaceuticals Trading Down 8.6%

The company has a debt-to-equity ratio of 1.08, a quick ratio of 1.27 and a current ratio of 1.43. The business has a 50-day simple moving average of $10.93 and a 200-day simple moving average of $9.64.

Institutional Trading of Telix Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of TLX. Rhumbline Advisers lifted its position in Telix Pharmaceuticals by 117.3% in the third quarter. Rhumbline Advisers now owns 2,579 shares of the company’s stock worth $25,000 after buying an additional 1,392 shares during the last quarter. Bank of America Corp DE increased its position in Telix Pharmaceuticals by 523.8% during the first quarter. Bank of America Corp DE now owns 10,031 shares of the company’s stock valued at $96,000 after acquiring an additional 8,423 shares during the last quarter. XTX Topco Ltd bought a new position in Telix Pharmaceuticals during the fourth quarter valued at $89,000. XY Capital Ltd purchased a new stake in shares of Telix Pharmaceuticals in the first quarter valued at $120,000. Finally, IHT Wealth Management LLC purchased a new stake in shares of Telix Pharmaceuticals in the second quarter valued at $213,000.

Telix Pharmaceuticals Company Profile

Telix Pharmaceuticals (NASDAQ: TLX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.

The company’s pipeline spans both imaging and therapeutic candidates.